Muhammad Reva Aditya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Reva Aditya has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Artha Maressa Theodora Simanjuntak
Department of Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
3 shared publicationsHikmawan Wahyu Sulistomo
Department of Pharmacology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
3 shared publicationsMichael Owen Hogipranata
Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
3 shared publications- Artha Maressa Theodora Simanjuntak
Department of Medicine Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada Yogyakarta Indonesia
2 shared publications - Christopher Daniel Tristan
Faculty of Medicine Surakarta Central Java Universitas Sebelas Maret
2 shared publications - Frengki Prabowo Saputro Wijayanto
Department of Medicine, Faculty of Medicine Public Health and Nursing Universitas Gadjah Mada Yogyakarta Indonesia
2 shared publications
Latest Publications
- 14 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Leadless Pacemakers After Transcatheter Aortic Valve Replacement: A Meta‐analysis With Time‐to‐Event Analysis
Background: Permanent pacemaker implantation is a common complication after transcatheter aortic valve replacement (TAVR). Leadless pacemakers (LPs) may reduce lead‐ and pocket‐related complications, but their clinical outcomes after TAVR remain uncertain. This systematic review and meta‐analysis evaluated the safety and effectiveness of LPs compared with transvenous pacemakers (TVPs). Methods: PubMed, Scopus, and ScienceDirect were searched from inception to June 10, 2026. Randomized and observational studies were included. Random‐effects meta‐analyses pooled proportions, risk ratios (RRs), and mean differences (MDs). Reconstructed Kaplan–Meier data were used to estimate hazard ratios (HRs). Results: Ten studies involving 10,809 patients (1030 LP and 9779 TVP recipients) were included. The pooled procedural success rate of LP implantation was 98% (95% CI 95%–99%). Implantation success was comparable between LP and TVP (RR 1.00, 95% CI 0.98–1.02). Sensitivity analysis demonstrated a shorter hospital stay with LP (MD −1.37 days, 95% CI −2.33 to −0.41) and a lower risk of heart failure hospitalization (RR 0.37, 95% CI 0.14–0.96). Overall survival did not differ between groups (HR 1.05, 95% CI 0.44–1.23), although reconstructed survival curves showed late separation favoring LP. Device‐related and vascular complications were comparable between LP and TVP. Conclusions: LP implantation after TAVR demonstrates excellent procedural success and clinical outcomes comparable to TVPs. LPs may reduce hospital stay and heart failure hospitalization, supporting their use as an alternative pacing strategy in appropriately selected patients.
- 14 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Leadless Pacemakers After Transcatheter Aortic Valve Replacement: A Meta‐analysis With Time‐to‐Event Analysis
Background: Permanent pacemaker implantation is a common complication after transcatheter aortic valve replacement (TAVR). Leadless pacemakers (LPs) may reduce lead‐ and pocket‐related complications, but their clinical outcomes after TAVR remain uncertain. This systematic review and meta‐analysis evaluated the safety and effectiveness of LPs compared with transvenous pacemakers (TVPs). Methods: PubMed, Scopus, and ScienceDirect were searched from inception to June 10, 2026. Randomized and observational studies were included. Random‐effects meta‐analyses pooled proportions, risk ratios (RRs), and mean differences (MDs). Reconstructed Kaplan–Meier data were used to estimate hazard ratios (HRs). Results: Ten studies involving 10,809 patients (1030 LP and 9779 TVP recipients) were included. The pooled procedural success rate of LP implantation was 98% (95% CI 95%–99%). Implantation success was comparable between LP and TVP (RR 1.00, 95% CI 0.98–1.02). Sensitivity analysis demonstrated a shorter hospital stay with LP (MD −1.37 days, 95% CI −2.33 to −0.41) and a lower risk of heart failure hospitalization (RR 0.37, 95% CI 0.14–0.96). Overall survival did not differ between groups (HR 1.05, 95% CI 0.44–1.23), although reconstructed survival curves showed late separation favoring LP. Device‐related and vascular complications were comparable between LP and TVP. Conclusions: LP implantation after TAVR demonstrates excellent procedural success and clinical outcomes comparable to TVPs. LPs may reduce hospital stay and heart failure hospitalization, supporting their use as an alternative pacing strategy in appropriately selected patients.
- Open Access
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 69-76
In hospital major adverse cardiovascular events in acute heart failure: prognostic role of echocardiographic pulmonary hypertension probability
Background: Pulmonary hypertension secondary to left heart disease (PH-LHD) is predominant type of pulmonary hypertension observed in hospitalized acute heart failure (AHF) patients. Bedside echocardiography for AHF patients offers a pragmatic approach for assessing probability of pulmonary hypertension (PH); however, data correlating the probability of PH as determined by echocardiography to in hospital major adverse cardiovascular events (MACE) throughout hospitalization remain limited. Methods: This retrospective cohort study was undertaken at a single location, gathered data from the AHF registry at Saiful Anwar General Hospital in Malang, Indonesia, from January 2024 to December 2025. Adult patients admitted for acute heart failure who had transthoracic echocardiography (TTE) within 24 hours of arrival were incorporated into study. The probabilities of pulmonary hypertension, assessed via echocardiography, has been classified as low, moderate, or high in accordance with the 2022 ESC/ERS criteria. The principal outcome was in hospital MACE, characterized as in hospital mortality, cardiac arrest necessitating resuscitation, and/or cardiogenic shock needing medicinal or mechanical hemodynamic intervention. A hierarchical multivariate logistic regression analysis was conducted, controlling for age, sex, body mass index (BMI), Killip, left ventricular ejection fraction (LVEF), utilization of mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitor (ARNI) medication. Result: A total of 403 patients (median age 61 years; 56.6% male) were enrolled in study, with in-hospital MACE occurring in 124 patients (30.8%). The MACE rate increased in parallel with the increase in PH probability categories: 25.7% (Low), 30.4% (Moderate), and 48.0% (High; p < 0.001). Multivariate analysis demonstrated that elevated PH probability was an independent predictor of in hospital MACE across all three hierarchical models (Model 1: OR 2.91, 95% CI 1.67–5.07; Model 2: OR 2.84, 95% CI 1.63–4.95; Model 3: OR 2.97, 95% CI 1.66–5.32; all p < 0.001), even after full adjustment for LVEF and therapy. Killip class was an independent predictor in all models (OR 1.51–1.77). Therapy use: Beta Blocker (BB) (OR 0.54), MRA (OR 0.43), and ARNI (OR 0.19) each independently reduced the risk of MACE. The resultant model exhibited satisfactory discrimination (AUC 0.73, 95% CI 0.68–0.78) and robust calibration (Hosmer Lemeshow p = 0.41. Conclusion: A high probability of PH assessed using echocardiography can detect high-risk AHF and independently forecast MACE during hospitalization, irrespective of LVEF, clinical severity, and treatment modalities. These findings support the use of echocardiography-based PH probability for early bedside risk determination in hospitalized AHF patient. Keyword : Acute Heart Failure; Echocardiography; Left Heart Disease; Major Adverse Cardiovascular Events; Pulmonary Hypertension.
- 13 October 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (4) , 69-76
Open AccessIn hospital major adverse cardiovascular events in acute heart failure: prognostic role of echocardiographic pulmonary hypertension probability
Background: Pulmonary hypertension secondary to left heart disease (PH-LHD) is predominant type of pulmonary hypertension observed in hospitalized acute heart failure (AHF) patients. Bedside echocardiography for AHF patients offers a pragmatic approach for assessing probability of pulmonary hypertension (PH); however, data correlating the probability of PH as determined by echocardiography to in hospital major adverse cardiovascular events (MACE) throughout hospitalization remain limited. Methods: This retrospective cohort study was undertaken at a single location, gathered data from the AHF registry at Saiful Anwar General Hospital in Malang, Indonesia, from January 2024 to December 2025. Adult patients admitted for acute heart failure who had transthoracic echocardiography (TTE) within 24 hours of arrival were incorporated into study. The probabilities of pulmonary hypertension, assessed via echocardiography, has been classified as low, moderate, or high in accordance with the 2022 ESC/ERS criteria. The principal outcome was in hospital MACE, characterized as in hospital mortality, cardiac arrest necessitating resuscitation, and/or cardiogenic shock needing medicinal or mechanical hemodynamic intervention. A hierarchical multivariate logistic regression analysis was conducted, controlling for age, sex, body mass index (BMI), Killip, left ventricular ejection fraction (LVEF), utilization of mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitor (ARNI) medication. Result: A total of 403 patients (median age 61 years; 56.6% male) were enrolled in study, with in-hospital MACE occurring in 124 patients (30.8%). The MACE rate increased in parallel with the increase in PH probability categories: 25.7% (Low), 30.4% (Moderate), and 48.0% (High; p < 0.001). Multivariate analysis demonstrated that elevated PH probability was an independent predictor of in hospital MACE across all three hierarchical models (Model 1: OR 2.91, 95% CI 1.67–5.07; Model 2: OR 2.84, 95% CI 1.63–4.95; Model 3: OR 2.97, 95% CI 1.66–5.32; all p < 0.001), even after full adjustment for LVEF and therapy. Killip class was an independent predictor in all models (OR 1.51–1.77). Therapy use: Beta Blocker (BB) (OR 0.54), MRA (OR 0.43), and ARNI (OR 0.19) each independently reduced the risk of MACE. The resultant model exhibited satisfactory discrimination (AUC 0.73, 95% CI 0.68–0.78) and robust calibration (Hosmer Lemeshow p = 0.41. Conclusion: A high probability of PH assessed using echocardiography can detect high-risk AHF and independently forecast MACE during hospitalization, irrespective of LVEF, clinical severity, and treatment modalities. These findings support the use of echocardiography-based PH probability for early bedside risk determination in hospitalized AHF patient. Keyword : Acute Heart Failure; Echocardiography; Left Heart Disease; Major Adverse Cardiovascular Events; Pulmonary Hypertension.
- Open Access
- 1 October 2026
- Published by InkVista Publishing House
- Vol. 19 (3) , 93-115
Serratus Plane Block as Promising Pain Management in Breast Cancer Surgery: An Updated Meta-Analysis
Background: Postoperative pain remains common after surgery, and opioid-related adverse effects motivate multimodal alternatives. The serratus plane block (SPB) is used for breast surgery, but its comparative benefit remains uncertain. Methods: We searched PubMed, the Cochrane Library, and ProQuest for English-language randomized trials and cohort studies published between January 2019 ...
- 1 October 2026
- Published by InkVista Publishing House
- Vol. 19 (3) , 93-115
Open AccessSerratus Plane Block as Promising Pain Management in Breast Cancer Surgery: An Updated Meta-Analysis
Background: Postoperative pain remains common after surgery, and opioid-related adverse effects motivate multimodal alternatives. The serratus plane block (SPB) is used for breast surgery, but its comparative benefit remains uncertain. Methods: We searched PubMed, the Cochrane Library, and ProQuest for English-language randomized trials and cohort studies published between January 2019 ...
- Open Access
- 24 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70452
Smoking and Risk of Atrial Fibrillation Recurrence After Catheter Ablation: A Meta‐Analysis and Meta‐Regression
Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide. Although catheter ablation is an established rhythm‐control strategy, recurrence remains frequent. Smoking is a potentially modifiable risk factor, but its impact on post‐ablation AF recurrence remains uncertain. This study evaluated the association between smoking status and AF recurrence following catheter ablation. Method: Six databases were searched up to March 2026. Studies including patients with AF undergoing first‐time catheter ablation and reporting recurrence outcomes stratified by smoking status were included. Sensitivity, subgroup, and meta‐regression analyses were performed. Publication bias was evaluated using Egger's test and trim‐and‐fill analysis. Result: Twenty‐two studies comprising 6047 participants were included. Smoking was associated with a significantly increased risk of AF recurrence following catheter ablation (OR 1.42, 95% CI: 1.09–1.85; p = 0.0096), with substantial heterogeneity ( I 2 = 65.8%). Sensitivity analysis confirmed the robustness of the findings (OR 1.35, 95% CI: 1.05–1.73). No significant small‐study effects were detected (Egger's p = 0.4280), although trim‐and‐fill analysis attenuated the association to borderline significance. Meta‐regression identified body mass index (BMI) as a significant moderator, with a weaker association observed in populations with higher BMI. Conclusion: Smoking is associated with a modest but significant increase in the risk of AF recurrence after catheter ablation. Future studies should evaluate the impact of smoking intensity, duration, and cessation on ablation outcomes using patient‐level data.
- 24 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70452
Open AccessSmoking and Risk of Atrial Fibrillation Recurrence After Catheter Ablation: A Meta‐Analysis and Meta‐Regression
Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide. Although catheter ablation is an established rhythm‐control strategy, recurrence remains frequent. Smoking is a potentially modifiable risk factor, but its impact on post‐ablation AF recurrence remains uncertain. This study evaluated the association between smoking status and AF recurrence following catheter ablation. Method: Six databases were searched up to March 2026. Studies including patients with AF undergoing first‐time catheter ablation and reporting recurrence outcomes stratified by smoking status were included. Sensitivity, subgroup, and meta‐regression analyses were performed. Publication bias was evaluated using Egger's test and trim‐and‐fill analysis. Result: Twenty‐two studies comprising 6047 participants were included. Smoking was associated with a significantly increased risk of AF recurrence following catheter ablation (OR 1.42, 95% CI: 1.09–1.85; p = 0.0096), with substantial heterogeneity ( I 2 = 65.8%). Sensitivity analysis confirmed the robustness of the findings (OR 1.35, 95% CI: 1.05–1.73). No significant small‐study effects were detected (Egger's p = 0.4280), although trim‐and‐fill analysis attenuated the association to borderline significance. Meta‐regression identified body mass index (BMI) as a significant moderator, with a weaker association observed in populations with higher BMI. Conclusion: Smoking is associated with a modest but significant increase in the risk of AF recurrence after catheter ablation. Future studies should evaluate the impact of smoking intensity, duration, and cessation on ablation outcomes using patient‐level data.
- 11 July 2026
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (7) , 77
Mechanisms of Cardiovascular Toxicity Induced by Silver Nanoparticles: A Systematic Review of Preclinical Evidence
Silver nanoparticles (AgNPs) have emerged as one of the most widely used nanomaterials in medical and consumer products, yet their cardiovascular safety remains inadequately characterized. While their antimicrobial properties are well-documented, accumulating evidence reveals that AgNPs pose a significant threat to the cardiovascular system. Exposure to AgNPs through inhalation, ingestion, or dermal contact enables these particles to enter systemic circulation, where they accumulate in cardiac and vascular tissues in a dose-, time-, and size-dependent manner. Once deposited, AgNPs initiate a cascade of pathological events, including oxidative stress, mitochondrial dysfunction, DNA damage, and disruption of calcium and sodium channel signaling. These molecular disturbances translate into physiological alterations such as bradycardia, atrioventricular conduction block, impaired contractility, and exacerbated ischemia-reperfusion injury. AgNPs also trigger endothelial activation, leading to upregulation of adhesion molecules, namely vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and recruitment of inflammatory cells, creating a proinflammatory and prothrombotic environment. Elevated cardiac biomarkers, including creatine kinase-MB fraction (CK-MB), brain natriuretic peptide (BNP), lactate dehydrogenase (LDH), and histopathological changes, including pericardial edema, myofibril disorganization, fibrosis, and inflammatory infiltration are consistently observed. Vascular dysfunction manifests as impaired vasorelaxation, enhanced vasoconstriction via endothelin-1 upregulation, thrombosis, and abnormal angiogenesis driven by vascular endothelial growth factor (VEGF) dysregulation. Although plant-based AgNPs have shown cardioprotective potential in limited studies, the overall evidence indicates significant cardiovascular risk. This systematic review synthesizes findings from 38 preclinical studies (35 in vivo, 3 in vitro), providing a comprehensive analysis of AgNP-induced cardiotoxicity with emphasis on oxidative stress, inflammation, and molecular dysregulation as core mechanistic drivers. Graphical Abstract
- 11 July 2026
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (7) , 77
Mechanisms of Cardiovascular Toxicity Induced by Silver Nanoparticles: A Systematic Review of Preclinical Evidence
Silver nanoparticles (AgNPs) have emerged as one of the most widely used nanomaterials in medical and consumer products, yet their cardiovascular safety remains inadequately characterized. While their antimicrobial properties are well-documented, accumulating evidence reveals that AgNPs pose a significant threat to the cardiovascular system. Exposure to AgNPs through inhalation, ingestion, or dermal contact enables these particles to enter systemic circulation, where they accumulate in cardiac and vascular tissues in a dose-, time-, and size-dependent manner. Once deposited, AgNPs initiate a cascade of pathological events, including oxidative stress, mitochondrial dysfunction, DNA damage, and disruption of calcium and sodium channel signaling. These molecular disturbances translate into physiological alterations such as bradycardia, atrioventricular conduction block, impaired contractility, and exacerbated ischemia-reperfusion injury. AgNPs also trigger endothelial activation, leading to upregulation of adhesion molecules, namely vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and recruitment of inflammatory cells, creating a proinflammatory and prothrombotic environment. Elevated cardiac biomarkers, including creatine kinase-MB fraction (CK-MB), brain natriuretic peptide (BNP), lactate dehydrogenase (LDH), and histopathological changes, including pericardial edema, myofibril disorganization, fibrosis, and inflammatory infiltration are consistently observed. Vascular dysfunction manifests as impaired vasorelaxation, enhanced vasoconstriction via endothelin-1 upregulation, thrombosis, and abnormal angiogenesis driven by vascular endothelial growth factor (VEGF) dysregulation. Although plant-based AgNPs have shown cardioprotective potential in limited studies, the overall evidence indicates significant cardiovascular risk. This systematic review synthesizes findings from 38 preclinical studies (35 in vivo, 3 in vitro), providing a comprehensive analysis of AgNP-induced cardiotoxicity with emphasis on oxidative stress, inflammation, and molecular dysregulation as core mechanistic drivers. Graphical Abstract
- 24 February 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (5) , 1-31
Modulating Gut Microbiota To Control Hypertension: A Systematic Review and Meta-Analysis of Probiotics, Postbiotics, Prebiotics and Synbiotics
- 24 February 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (5) , 1-31
Modulating Gut Microbiota To Control Hypertension: A Systematic Review and Meta-Analysis of Probiotics, Postbiotics, Prebiotics and Synbiotics
- Open Access
- 16 December 2025
- Published by Indonesian Journal of Cardiology in Indonesian Journal of Cardiology
- Vol. 46 (4) , 171-182
Could Cardiac Shockwave Therapy be the Breakthrough Solution for Refractory Angina? A Systematic Review and Meta-Analysis
Background: Refractory angina (RA) is a chronic condition unresponsive to standard treatments like PCI or CABG, leaving limited options for many patients. Cardiac shockwave therapy (CSWT) is a novel, noninvasive approach that enhances myocardial perfusion through microvascular regeneration. This systematic review and meta-analysis evaluate the effectiveness of CSWT in managing RA. Methods: A comprehensive literature search was conducted using electronic databases (Cochrane, PubMed, and ScienceDirect), including comparative studies with controls that evaluated CSWT in RA patients between 2010 and 2024. Studies not in English, with irrelevant outcomes, or lacking full-text access, were excluded. Data were extracted and analyzed using a random-effects model to address heterogeneity. Results: Seven studies, including 3 randomized controlled trials (RCTs) and 4 observational studies, with a total of 417 patients were analyzed. CSWT demonstrated significant improvements in multiple clinical outcomes. CSWT reduces angina severity in CSWT reduces angina severity in CCS grade (MD -0.76, 95% CI -0.97, -0.55, P < 0.00001) and in NYHA class (MD -0.62, 95% CI -0.95, -0.30, P = 0.0002), increased the 6- Minute Walk Test (6MWT) distance by 57.63 meters (MD 57.63, 95% CI 16.71, 98.54, P = 0.006), increased SAQ scores by 10.96 points (MD 10.96, 95% CI 1.66, 20.26, P = 0.02), improved LVEF by 4.43% (MD 4.43, 95% CI: 2.66 to 6.21, P< 0.01), and decreased nitroglycerin usage by 1.62 intake per week (MD -1.62, 95% CI -2.61, -0.62, P = 0.001). However, there was no significant difference in LVEDD between the two groups. Conclusion: CSWT appears to be a promising therapeutic option for patients with RA, demonstrating improvement in CCS angina class, NYHA class, 6-min walk test distances, SAQ score, LVEF, and reduces nitroglycerin usage. Keyword: Cardiac Shockwave Therapy, Refractory Angina, Non-invasive Cardiac Therapy, Chronic Angina Treatment, Innovative Angina Therapies
- 16 December 2025
- Published by Indonesian Journal of Cardiology in Indonesian Journal of Cardiology
- Vol. 46 (4) , 171-182
Open AccessCould Cardiac Shockwave Therapy be the Breakthrough Solution for Refractory Angina? A Systematic Review and Meta-Analysis
Background: Refractory angina (RA) is a chronic condition unresponsive to standard treatments like PCI or CABG, leaving limited options for many patients. Cardiac shockwave therapy (CSWT) is a novel, noninvasive approach that enhances myocardial perfusion through microvascular regeneration. This systematic review and meta-analysis evaluate the effectiveness of CSWT in managing RA. Methods: A comprehensive literature search was conducted using electronic databases (Cochrane, PubMed, and ScienceDirect), including comparative studies with controls that evaluated CSWT in RA patients between 2010 and 2024. Studies not in English, with irrelevant outcomes, or lacking full-text access, were excluded. Data were extracted and analyzed using a random-effects model to address heterogeneity. Results: Seven studies, including 3 randomized controlled trials (RCTs) and 4 observational studies, with a total of 417 patients were analyzed. CSWT demonstrated significant improvements in multiple clinical outcomes. CSWT reduces angina severity in CSWT reduces angina severity in CCS grade (MD -0.76, 95% CI -0.97, -0.55, P < 0.00001) and in NYHA class (MD -0.62, 95% CI -0.95, -0.30, P = 0.0002), increased the 6- Minute Walk Test (6MWT) distance by 57.63 meters (MD 57.63, 95% CI 16.71, 98.54, P = 0.006), increased SAQ scores by 10.96 points (MD 10.96, 95% CI 1.66, 20.26, P = 0.02), improved LVEF by 4.43% (MD 4.43, 95% CI: 2.66 to 6.21, P< 0.01), and decreased nitroglycerin usage by 1.62 intake per week (MD -1.62, 95% CI -2.61, -0.62, P = 0.001). However, there was no significant difference in LVEDD between the two groups. Conclusion: CSWT appears to be a promising therapeutic option for patients with RA, demonstrating improvement in CCS angina class, NYHA class, 6-min walk test distances, SAQ score, LVEF, and reduces nitroglycerin usage. Keyword: Cardiac Shockwave Therapy, Refractory Angina, Non-invasive Cardiac Therapy, Chronic Angina Treatment, Innovative Angina Therapies
- Open Access
- 20 August 2025
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 19, e17
Exploring Exercise-induced Long QT: A Scoping Review of Reversibility Through Detraining and Distinction from Long QT Syndrome
Exercise-induced long QT may mimic congenital long QT syndrome (LQTS), risking misdiagnosis and unnecessary treatment. This scoping review explores its reversibility through detraining and differentiation from congenital LQTS. A systematic search of five databases identified six studies involving 196 subjects. Results showed that exercise-induced long QT is reversible, with QT intervals normalizing after detraining, typically over 1–6 months. Unlike congenital LQTS, affected athletes often lacked genetic mutations or family histories linked to the condition. The difference between congenital LQTS and exercise-induced long QT lies in the reversibility of QT interval prolongation. In those with exercise-induced long QT, the prolonged QT interval would return to normal levels with detraining, unlike in congenital LQTS. Further long-term follow-up is needed to assess the potential arrhythmic risk associated with re-exposure to intensive training. Additionally, negative genetic testing and absence of family history do not entirely exclude congenital LQTS nor indicate benignity, emphasizing the need for careful clinical assessment beyond these factors.
- 20 August 2025
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 19, e17
Open AccessExploring Exercise-induced Long QT: A Scoping Review of Reversibility Through Detraining and Distinction from Long QT Syndrome
Exercise-induced long QT may mimic congenital long QT syndrome (LQTS), risking misdiagnosis and unnecessary treatment. This scoping review explores its reversibility through detraining and differentiation from congenital LQTS. A systematic search of five databases identified six studies involving 196 subjects. Results showed that exercise-induced long QT is reversible, with QT intervals normalizing after detraining, typically over 1–6 months. Unlike congenital LQTS, affected athletes often lacked genetic mutations or family histories linked to the condition. The difference between congenital LQTS and exercise-induced long QT lies in the reversibility of QT interval prolongation. In those with exercise-induced long QT, the prolonged QT interval would return to normal levels with detraining, unlike in congenital LQTS. Further long-term follow-up is needed to assess the potential arrhythmic risk associated with re-exposure to intensive training. Additionally, negative genetic testing and absence of family history do not entirely exclude congenital LQTS nor indicate benignity, emphasizing the need for careful clinical assessment beyond these factors.
- Open Access
- 23 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 3987
Determining the Risk of Type 2 Diabetes for rs1801133 Genotypes in Multiethnic Populations: A Global Meta-Epidemiological Study
The rs1801133 (C677T) polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene has been linked to type 2 diabetes (T2D) risk. This study aimed to assess the association between rs1801133 genotypes (CC, CT, TT) and T2D across multiethnic populations and to identify genotype- and region-specific risks. A global meta-epidemiological analysis was conducted using data from 19 studies comprising 6479 participants from Asia, Africa, Europe, and America. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by region were also performed. The results of the CC vs. CT dominant genetic model were OR 95% CI = 0.63 (0.46–0.87); p = 0.005; the CC vs. TT genetic recessive model yielded OR 95% CI = 0.59 (0.38–0.91); p = 0.02; and the CT vs. TT codominance genetic model yielded OR 95% CI = 0.95 (0.65–1.37); p = 0.78. Based on the subgroup analysis, the CC genotype is predominantly associated with an increased risk of T2D in both Africa and Europe. From this study, the CC genotype was proven to be highly contributory to T2D risk compared to the CT and TT genotypes. These findings highlight the need for ethnicity-informed genetic screening and targeted prevention strategies in global diabetes management.
- 23 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 3987
Open AccessDetermining the Risk of Type 2 Diabetes for rs1801133 Genotypes in Multiethnic Populations: A Global Meta-Epidemiological Study
The rs1801133 (C677T) polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene has been linked to type 2 diabetes (T2D) risk. This study aimed to assess the association between rs1801133 genotypes (CC, CT, TT) and T2D across multiethnic populations and to identify genotype- and region-specific risks. A global meta-epidemiological analysis was conducted using data from 19 studies comprising 6479 participants from Asia, Africa, Europe, and America. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by region were also performed. The results of the CC vs. CT dominant genetic model were OR 95% CI = 0.63 (0.46–0.87); p = 0.005; the CC vs. TT genetic recessive model yielded OR 95% CI = 0.59 (0.38–0.91); p = 0.02; and the CT vs. TT codominance genetic model yielded OR 95% CI = 0.95 (0.65–1.37); p = 0.78. Based on the subgroup analysis, the CC genotype is predominantly associated with an increased risk of T2D in both Africa and Europe. From this study, the CC genotype was proven to be highly contributory to T2D risk compared to the CT and TT genotypes. These findings highlight the need for ethnicity-informed genetic screening and targeted prevention strategies in global diabetes management.